Restoration of defective EA(G)-rosetting capacity of cancer patient neutrophils by levamisole

F. Patrone, F. Dallegri, V. Pistoia

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the 'immunomodulating' effect of the drug.

Original languageEnglish
Pages (from-to)1668-1672
Number of pages5
JournalCancer
Volume55
Issue number8
Publication statusPublished - 1985

Fingerprint

Levamisole
Fc Receptors
Neutrophils
Neoplasms
Phagocytosis
Pharmaceutical Preparations
Antibodies
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Restoration of defective EA(G)-rosetting capacity of cancer patient neutrophils by levamisole. / Patrone, F.; Dallegri, F.; Pistoia, V.

In: Cancer, Vol. 55, No. 8, 1985, p. 1668-1672.

Research output: Contribution to journalArticle

@article{5a3bee420e6d48458ddbe8f825460c5c,
title = "Restoration of defective EA(G)-rosetting capacity of cancer patient neutrophils by levamisole",
abstract = "Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the 'immunomodulating' effect of the drug.",
author = "F. Patrone and F. Dallegri and V. Pistoia",
year = "1985",
language = "English",
volume = "55",
pages = "1668--1672",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Restoration of defective EA(G)-rosetting capacity of cancer patient neutrophils by levamisole

AU - Patrone, F.

AU - Dallegri, F.

AU - Pistoia, V.

PY - 1985

Y1 - 1985

N2 - Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the 'immunomodulating' effect of the drug.

AB - Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the 'immunomodulating' effect of the drug.

UR - http://www.scopus.com/inward/record.url?scp=0021895189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021895189&partnerID=8YFLogxK

M3 - Article

C2 - 3978560

AN - SCOPUS:0021895189

VL - 55

SP - 1668

EP - 1672

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -